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Figure 1. Weibull model visualizing the relationship between busulfan
exposure and the probability of EFS (highest EFS rates at 75-100mg*h/L, HR ¼
0.37, 95% CI 0.15-0.92 compared to <50mg*h/L).
Figure 2. Weibull models visualizing the relationship between busulfan
exposure and EFS, by underlying disease.
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targets for exposure are however primarily based on adult
studies. Therefore, this study aimed to deﬁne the optimal
therapeutic target of BU in children and identify other patient-
speciﬁc variables to optimize outcomes following alloHCT.
Methods: This retrospective study utilized exposure-
response data available from routine pharmacokinetic anal-
ysis with or without TDM of BU levels in children and young
adults treated with HCT between the years of 2000-2013
from 13 different centers. Primary endpoints were event-free
survival (EFS) and overall survival (OS). Secondary endpoints
included treatment-related mortality (TRM), veno-occlusive
disease (VOD), acute graft-versus-host disease (aGVHD)
grade IIeIV and cGVHD. A predictor analysis using Cox
regression and multivariate Weibull models was performed.
Results: A total of 685 subjects (range 11-116 per center)
treated for a variety of malignant (n¼318) and non-malig-
nant disorders (n¼367), with a median age of 5.0 years
(range 0.1-28.7) were included in the analysis. The median
cumulative BU area-under-the-concentration-curve (AUC)
was 77mg*hr/L (range 21-160). In all patients, three-year
probability of EFS, OS and graft failurewas 72%, 79%, and 5.4%
respectively. BU AUC below 75 or above 100mg*hr/L
(p¼0.03), “ex-vivo T-cell depletion” (p¼0.02) and “in vivo T-
cell depletion using serotherapy” (ATG or alemtuzumab:
p¼0.02) were negative predictors of EFS. A U-shaped rela-
tionship between BU AUC & EFS was observed (Figure 1). In
patients with malignant disease optimal BU AUC was lower
compared to non-malignant disorders (83-95mg*hr/L vs
99-111 mg*h/L, p¼0.04, Figure 2). Below the optimal BU
target, the incidence of graft failure and relapse (malignant
only) was higher (p¼0.01), while above the target TRMincreased (p¼0.04). BU AUC above the median and addition
of melphalan were both independently associated with the
risk of aGvHD (p¼0.01, p¼0.04), and melphalan use further
increased the risk of VOD (p<0.01). No association was
found with cGvHD.
Conclusion: BU AUC targeted to a narrow therapeutic range,
which is indication dependent, (83-95 mg*h/L for malignant
and 99-111mg*h/L for non-malignant diseases) was found to
increase EFS andOS in children. Lower BUAUCwas associated
with graft-failure and relapse and higher BU AUC with TRM.
Our ﬁndings suggest that personalizing BU AUC by patient-
speciﬁc factors may improve efﬁcacy and reduce toxicity.102
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Stem cell transplantation for patients with non-malignant
disorders is often challenging,with frequent failure to engraft.
In the absence of an HLA-identical source, there is no
consensus about the best alternative hemopoietic stem cell
donor for patients who lack amatched sibling. Although cord
blood transplant has been a recent option for these patients,
an increased risk of viral infections and the potential for failed
engraftment have remained problematic and associated with
signiﬁcant mortality. We therefore studied 25 children who
underwent UCBT transplant at our institution for non-ma-
lignant disorders between 2007 and 2014. Their median age
was 8months (range, 2e66months) an their diagnoseswere:
SCID (n¼17), IPEX (n¼2), LAD (n¼1), Wiskott-Aldrich syn-
drome (n¼1), Krabbe (n¼1), mannosidosis (n¼1), HLH (n¼1),
and Diamond-Blackfan anemia (n¼1). Five patients had
persistent viral infections prior to transplant: RSV (n¼2),
Parainﬂuenza 3 (n¼1), VZV (n¼1) andNorovirus (n¼1), and 7
(30%) patients had required mechanical ventilation prior to
transplantation. Eight of 25 patients were 6/6 HLA antigen
matchedwith their cord stemcell donor, and17wereoneHLA
antigenmismatched.All patientsparticipated inaprospective
trial consisting of myeloablative conditioning using busulfan,
cyclophosphamide and ﬂudarabine without the use of sero-
therapy. The median total nucleated cell dose in the trans-
plant was 10x107 TNC/kg (range, 5.9e25.4). The median time
to neutrophil recovery was 19 days (range,8-30) and the
median time to platelet recoverywas 38 days (range, 26-127).
All but one evaluable patient achieved full donor chimerism
(deﬁned as> 95% donor cells in peripheral blood) by day +42.
The exception was a patient with Krabbe’s disease who is
nonetheless 60% donor chimeric at 6 months post-transplant
with normalization of enzyme levels. No severe aGVHD or
cGVHD has occurred and only one patient developed grade II
aGVHD (skin). All except the patient with HLH (who died of
Table 2
Patient outcomes
Characteristic Number/Median (range)
Days to Neutrophil engraftment 9 (7-15)
Days to Platelet engraftment 16 (11-230)
Complication
Oral mucositis 23
Hyperbilirubinemia 10
Hypertension 12
Sinusoidal obstruction syndrome (SOS)* 1
Infections (number of patients) 26
- Bacterial 11
- Viral 21
- Fungal 3
GVHD
Acute GVHD
- Acute Gr I-II 4
- Acute Gr III-IV 0
Chronic GVHD
- Chronic, limited 3
- Chronic, extensive 0
Fig 1. One-year probabilities of overall survival and disease free survival.
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years (range, 10 dayse5 years) and a 3-yr OS by KaplanMeier
analysis of 96% (95%CI: 73%-99%). All patients with viral in-
fections at the time of transplant cleared the infection at a
median time of 51 days (range, 44-54). ELISPOT analyses of
peripheral blood at the time that infections responded
showed signiﬁcant T cell responses against the pertinent vi-
ruses. All evaluable patients have normalization of their im-
mune or metabolic defect including adequate B cell function
in SCID patients. Hence, UCBTafter full intensity conditioning
without serotherapy forpediatricnon-malignantdiseases can
produce rapid functional engraftment and immune-recon-
stitution in the absence of signiﬁcant GVHD, leading to
excellent overall survival.
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Objective: This multi-institutional study was designed to
optimize outcomes of alternative donor HCT in patients with
FA without using total body irradiation (TBI). TBI was
replaced by busulfan (BU) (to reduce the risk of secondary
solid tumors) and BU dose was reduced after ﬁrst 25 patients
to ﬁnd the lowest acceptable BU dose.
Methods: 45 patients were transplanted from June 2009 to
May 2014. These included patients with prior transfusions,
androgen use and myelosdysplastic syndrome. Patient de-
mographics, disease and donor characteristics are described
in Table 1.Table 1
Patient demographics
Characteristics Number/Median (Range)
Median age in years 8.2 (4.3-44)
<10 years of age 27
10 years of age 18
Gender
- Males 20
- Females 25
Severe Single Lineage Cytopenia 5
Severe Aplastic Anemia 29
Myelodysplastic Syndrome 11
- Low grade 7
- High grade 4
Donor type
Matched Unrelated (8/8 match) 25
Mismatched Unrelated (7/8 match) 14
Mismatched Related (4/8, 5/8, 6/8 match) 5
Phenotypically Matched Related (8/8) 1
Follow-up in months, Median and Range 21.3 (2.6 - 61)Preparative regimen included: BU (BU) 0.8-1.0 mg/Kg/
dose IV (ﬁrst 25 patients) and 0.6-0.8 mg/kg/dose Q 12H
(next 20 patients) x 4 doses, cyclophosphamide (10mg/kg/
dose), ﬂudarabine (35mg/m2/dose) and rabbit ATG(2.5mg/
kg/dose) daily x 4 days. BU doses were adjusted based on
pharmacokinetics of the ﬁrst dose. All grafts were T-cell
depleted using the CliniMacs CD34 columns (Miltenyi).
GvHD prophylaxis was cyclosporine.
Results: 43patientsengrafted.Onepatienthad lategraft failure
and one had early relapse of MDS. See Table 2 for detailed
results and transplant outcomes. One patient (#3) developed
sinusoidal obstruction syndrome of liver. However, after
reducing the BU goal level, no further SOS observed.
36 of the 45 patients are alive. Causes of death included
infection (n¼5), multi-organ failure (n¼3), and severe pul-
monary hypertension (n¼1). One year probability of overall
and disease free survival for the entire cohort was 79.2%
(+/-6.2%) and 76.7 (+/-6.5%) respectively (Fig 1). OS for pa-
tients <10 years of age transplanted for marrow failure was
91.3% (+/-5.9%) similar to that reported for historical matched
sibling donor HCT outcomes.
Conclusion: This chemotherapy only preparative regimen
leads to excellent outcomes in patients undergoing
